INTRODUCTION
============

Epithelial ovarian carcinoma (EOC) has the highest mortality among gynecologic malignancies, accounting for 4.2% of all cancer-related deaths in women \[[@B1]\]. Although EOC is often thought of as a single entity, the different histological subtypes including clear cell carcinoma (CCC), serous adenocarcinoma (SAC), mucinous adenocarcinoma, and endometrioid adenocarcinoma vary in molecular, clinical, and pathological characteristics \[[@B2]\]. Accounting for approximately 5%--25% of EOCs, ovarian clear cell carcinoma (OCCC) is presented with the highest incidences reported in people of Asiatic origin \[[@B3]\]. Microscopically, it is characterized by cells with clear cytoplasm (that contains glycogen) and hob nail cells (from which the glycogen has been secreted). Typically, early stage OCCC is known to have a favorable outcome; however, patients with advanced disease have poorer prognosis when compared to high-grade serous ovarian cancer (HGSOC) \[[@B4]\]. Data suggested that the standard treatment including the debulking surgery followed by systemic chemotherapy may be less effective in OCCC with advanced stages, owing to its resistance toward chemotherapeutic agents \[[@B5][@B6]\]. Therefore, improved therapeutic strategies are absolutely required in the management of women with OCCC.

Tumor-induced immune suppression is a key problem that not only promotes tumor development, but also inhibits the efficiency of anti-cancer treatment. One of the major molecular regulators of tumor immune escape is programmed death-ligand 1 (PD-L1, CD274, B7-H1), a cell-surface protein induced in a number of malignancies, which could help tumor cells immune evasion in combination with immonomodulatory properties \[[@B7]\]. Blockage of PD-L1 expression on tumor cells might activate tumor-specific T cell to kill tumor cells by mediating tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) \[[@B8][@B9]\]. Previous studies have shown that PD-L1 can be expressed in a number of malignancies including melanoma (MEL), non-small cell lung cancers (NSCLCs), renal cell carcinomas (RCCs), cancers of head and neck, and gastrointestinal malignancies \[[@B10][@B11][@B12][@B13][@B14]\], and was correlated with unfavorable prognosis and the resistance to anticancer therapies in non-small lung cancers, colorectal and breast cancers \[[@B15][@B16][@B17]\]. Although several literatures showed that PD-L1 expression was upregulated in EOCs, most studies were conducted only in serous ovarian cancer (OC) \[[@B18][@B19][@B20]\]. Therefore, we focused our work to investigate the PD-L1 expression and its correlation with clinicopathological features in OCCC, and to further explore the prognostic value of PD-L1 expression in OCCC.

MATERIALS AND METHODS
=====================

1. Patients {#sec1}
-----------

A total of 138 patients diagnosed with OCCC were selected from the archival collections (between 1999 and 2014) of the Department of Pathology at Fudan University Shanghai Cancer Center. The exclusion criteria included patients with previously treated OCCC, patients with malignancies other than OCCC, patients with a simultaneous second primary cancer, patients with a previous history of chemo-radiotherapy due to other diseases and patients without follow-up infomation. Of the whole series, 122 patients with adequate paraffin-embedded tissue for immunohistochemical evaluation were enrolled in the study of the PD-L1 expression. All the 122 cases had undergone primary operation and received no chemotherapy before surgery. The detailed clinical data were collected by reviewing patients\' medical charts. In order to confirm the diagnosis, all the microscopic slides were reviewed by the same gynecology-dedicated pathologist (Wu Y) and confirmed by a second experienced gynecologic pathologist (Bi R). Both were blinded to the original diagnosis. The histologic subtype was classified according to the World Health Organization (WHO) definitions \[[@B21]\].

All the 122 patients in the study cohort provided informed consent. The study was approved by the ethics committee at Fudan University Shanghai Cancer Center, Shanghai, China. All of the participants provided written informed consent for the use of their tissue samples.

Patients were staged using the International Federation of Gynecology and Obstetrics (FIGO) 2012 staging system and were further divided into early stage (I--II) and advanced stage (III--IV) for the purpose of statistical analysis. The vast majority of the patients received platinum-based chemotherapy regimens with the number of cycles ranging from 6 to 8. Operations were performed by gynecologic oncologist to achieve optimal cytoreduction, which was defined as residual disease less than (or including) 1 cm after primary debulking. The platinum-sensitive (PS) patients were defined as the length of the platinum-free interval (PFI) of more than 6 months after completion of the last platinum-based regimen, while the platinum-resistant (PR) disease with a PFI less than 6 months.

2. Construction of the tissue microarray (TMA) {#sec2}
----------------------------------------------

TMAs were constructed in the present study. In brief, hematoxylin and eosin (H&E) sections were assessed and an appropriate area of tumor was marked on the corresponding paraffin block. Care was taken not to include areas of fibrosis, adipose tissue or necrosis. Duplicate of 0.8 mm diameter cylinders were punched from representative tumor areas of individual donor tissue block, and re-embedded into a recipient paraffin block at a defined position, using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD, USA). Following a review and screening of the representative tumor regions, 3 different areas were selected to cover the intratumoral heterogeneity for each tumor. Four TMA blocks were built at Fudan University Shanghai Cancer Center biorepository facility.

3. Immunohistochemistry (IHC) {#sec3}
-----------------------------

TMAs were immunohistochemically stained. Primary antibodies used for IHC included anti-PD-L1 antibody (Ab) (ab205921, 1:50 dilution ratio; Abcam, Cambridge, MA, USA). The tissue sections were deparaffinized in xylene (2×20 minutes) and subjected to a graded alcohol dehydration (95%, 90%, 80%, and 70%) to water. Heat-mediated antigen retrieval was performed with ethylenediaminetetraacetic acid (EDTA) buffer (pH=8) by microwaves for 23 minutes. To block endogenous peroxidase activity, all sections were treated with 100% methanol containing 0.3% H~2~O~2~ at room temperature for 25 minutes. The sections were incubated with rabbit anti-PD-L1 monoclonal Ab overnight at 4°C. Then, the sections were incubated with a biotinylated goat-anti-rabbit secondary Ab (K5007; Dako, Glostrup, Denmark), followed by an incubation with a streptavidin-peroxidase complex solution at room temperature for 50 minutes and counterstained with hematoxylin. Positive controls consisted of placenta tissue for the primary antibody and the normal ovarian tissue was used for the negative control.

4. Assessment of PD-L1 expression {#sec4}
---------------------------------

Two gynecological pathologists independently examined the prepared immunohistochemical slides without any prior information on the clinical history of the patients. The proportion of PD-L1-positive cells was estimated as a percentage of the total tumor cells. The tumor cells typically showed membranous staining with a variably strong component of cytoplasmic staining. Immunohistochemical evaluation of PD-L1 in OCCC specimens was based on the intensity and extent of nuclear and cytoplasmic reactivity. A 10% threshold of cell surface PD-L1 expression on tumor cells was defined as positive. The tumor cells typically showed membranous staining with a variably strong component of cytoplasmic staining. Then, we defined samples with barely no positive cells, less than 10% of positive cells, 10%--50% of positive cells, more than 51% of positive cells as negative, weak, moderate, strong expression, respectively. Tumors with moderate and strong staining were considered to be high expression of PD-L1 \[[@B22]\].

5. Statistical analysis {#sec5}
-----------------------

Statistical comparisons between clinicopathologic features and PD-L1 expression were evaluated using a χ^2^ test, whereas Fisher\'s exact test was added as necessary during the statistical analysis. In the analysis of recurrence and survival, the start point was defined as the day of surgery was performed. The end of the progression-free survival (PFS) period was defined as the day of recurrence, and that of overall survival (OS) period was defined as the day confirmed alive or dead, respectively. Estimation of PFS and OS was calculated by the Kaplan-Meier method, and the curves were compared using a log-rank test. Possible risk factors for recurrence and OS were analyzed with a Cox proportional hazards model. All of the p-values reported were 2-sided, and a value of p\<0.05 was considered statistically significant. Statistical Package for Social Science (SPSS) statistical software (version 20.0; SPSS Inc., Chicago, IL, USA) and GraphPad Prism (version 5.0; GraphPad Software Inc., La Jolla, CA, USA) were used for all of the analyses.

RESULTS
=======

1. Demographic and clinicopathologic characteristics {#sec1___1}
----------------------------------------------------

Demographics and clinicopathologic characteristics are summarized in [Table 1](#T1){ref-type="table"}. A total of 122 eligible patients were enrolled with a median postoperative follow-up term of 33.1 months (range, 1.7--163.4 months). The median age with a diagnosis of clear cell histology was 53.0 years (range, 19--83).

###### Univariate analysis of factors associated with PFS and OS

![](jgo-28-e77-i001)

  Factors                           No.              Recurrent (%)   p-value      Death (%)   p-value
  --------------------------------- ---------------- --------------- ------------ ----------- ---------
  Age at diagnosis (yr)                                              0.368                    0.848
                                    ≤55              76              32 (42.1)    24 (31.6)   
                                    \>55             46              23 (50.0)    15 (32.6)   
  Family history of malignancy                                       0.843                    0.702
                                    Yes              30              13 (45.7)    9 (30.0)    
                                    None             92              42 (43.3)    30 (32.6)   
  Menopause                                                          0.753                    0.395
                                    Postmenopausal   75              33 (44.0)    23 (30.7)   
                                    Premenopausal    47              22 (46.8)    16 (34.0)   
  BMI                                                                0.880                    0.888
                                    ≤25              61              27 (44.3)    18 (29.5)   
                                    \>25             61              28 (45.9)    21 (34.4)   
  Pretreatment CA125 level (U/mL)                                    0.002                    0.023
                                    \<244            55              18 (32.7)    13 (23.6)   
                                    ≥244             52              30 (57.7)    19 (36.5)   
  Ascites                                                            0.133                    0.077
                                    Negative         68              27 (39.7)    18 (26.5)   
                                    Positive         49              25 (51.0)    18 (36.7)   
  Tumor site                                                         0.001                    \<0.001
                                    Unilateral       99              39 (39.4)    26 (26.3)   
                                    Bilateral        23              16 (69.6)    13 (56.5)   
  Tumor volume (cm)                                                  0.139                    0.038
                                    \<10             49              26 (53.1)    21 (42.9)   
                                    ≥10              73              29 (39.7)    18 (24.7)   
  Tumor stage                                                        \<0.001                  \<0.001
                                    I                57              10 (17.5)    5 (7.9)     
                                    II               19              8 (42.1)     6 (30.0)    
                                    III              36              28 (77.8)    25 (58.1)   
                                    IV               10              9 (90.0)     8 (80.0)    
  Residual disease (cm)                                              \<0.001                  \<0.001
                                    R~0~             98              36 (36.7)    23 (23.5)   
                                    ≤1               18              13 (72.2)    10 (55.6)   
                                    \>1              6               6 (100.0)    6 (100.0)   
  Sensitivity to chemotherapy                                        \<0.001                  \<0.001
                                    Sensitive        81              14 (17.3)    7 (8.6)     
                                    Insensitive      40              40 (100.0)   31 (77.5)   
  PD-L1 expression                                                   0.021                    0.001
                                    Low              68              25 (36.8)    13 (19.1)   
                                    High             54              30 (55.6)    26 (48.1)   

BMI, body mass index; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R~0~, no visible residual disease.

At the completion of the primary surgery, 80.5% of the patients (n=99) had no visible residual disease (R~0~), 14.6% of the patients (n=18) had residual disease ≤1 cm, and 4.9% of the advanced cases (n=6) had residual disease \>1 cm. The vast majority (98.4%, n=121) of the patients received adjuvant chemotherapy with platinum-based regimens, while only 2 patients received the traditional Chinese medicine instead of chemotherapy.

2. Immunohistochemical detection of PD-L1 expression in OCCC {#sec2___1}
------------------------------------------------------------

PD-L1 was stained using IHC techniques on the cell membrane or in the cytoplasm of epithelial tumor cells and the immunohistochemical PD-L1 expression was depicted in [Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. Among all 123 cases, 55 cases (44.7%) were categorized as having high PD-L1 expression (PD-L1^high^) and 68 cases (55.3%) were presented with low PD-L1 expression (PD-L1^low^). When stratified by FIGO stage, PD-L1^high^ was observed in 22 of 58 stage I cases (37.9%), 7 of 19 stage II cases (36.8%), 20 of 36 stage III cases (55.6%), and 6 of 10 stage IV cases (60.0%). In PS patients, PD-L1^high^ was observed in 31 cases (38.3%), and 50 cases (61.7%) were presented with low expression. While among PR patients, 23 cases (57.5%) were found to have PD-L1^high^ and PD-L1^low^ was displayed in 17 cases (42.5%).

![The overview of staining intensities of the tissue array is shown (3+. 2+, 1+, and 0+), with an example each (A-D) for a membranous and/or for a cytoplasmic staining pattern.](jgo-28-e77-g001){#F1}

![Immunohistochemical staining for PD-L1 in OCCC tumor tissues. The staining intensities are shown (0+, 1+, 2+, 3+), with an example each (A-D) for a membranous and/or a cytoplasmic staining pattern. The placenta tissue (E) is used as a positive control for PD-L1 expression. The total number of each staining intensity are shown in (F).\
OCCC, ovarian clear cell carcinoma; PD-L1, programmed death-ligand 1.](jgo-28-e77-g002){#F2}

3. Statistical association between PD-L1 expression and clinicopathologic features in OCCC {#sec3___1}
------------------------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows the clinicopathologic characteristics in relation to PD-L1 expression. PD-L1^high^ was significantly associated with advanced stages (III--IV) compared to PD-L1^low^ (57.4% vs. 42.6%, p=0.020). Additionally, PD-L1^high^ tended to be associated with positive ascitic fluid rather than negative ascitic fluid (57.1% vs. 42.9%, p=0.016). Recurrent OCCC patients with PR appeared to exhibit elevated expression of PD-L1 (57.5% vs. 42.5%, p=0.045). Recurrent diseases seemed to present PD-L1^high^ than those diseases with no relapse (54.5% vs. 45.5%, p=0.038).

###### Correlations between the expression of PD-L1 and clinicopathological characteristics in OCCCs

![](jgo-28-e77-i002)

  Variables                     Tumoral PD-L1 expression               
  ----------------------------- -------------------------- ----------- -----------
  Age (yr)                                                             0.260
                                ≤55                        39 (57.4)   37 (68.5)
                                \>55                       29 (42.6)   17 (31.5)
  Stage                                                                0.020
                                Early (I--II)              48 (70.6)   27 (50.0)
                                Advanced (III--IV)         20 (29.4)   27 (50.0)
  BMI                                                                  0.068
                                ≤25                        29 (42.6)   32 (59.3)
                                \>25                       39 (57.4)   22 (40.7)
  Menopause status                                                     0.264
                                Premenopausal              23 (33.8)   24 (44.4)
                                Postmenopausal             45 (66.2)   30 (55.6)
  Pretreatment CA125 (U/mL)                                            0.699
                                \<244                      32 (53.3)   23 (48.9)
                                ≥244                       28 (46.7)   24 (51.1)
  Ascitic fluid                                                        0.016
                                Negative                   45 (68.2)   23 (45.1)
                                Positive                   21 (31.8)   28 (54.9)
  Tumor site                                                           0.245
                                Unilateral                 58 (85.3)   41 (75.9)
                                Bilateral                  10 (14.7)   13 (24.1)
  Tumor volume (cm)                                                    0.854
                                \<10                       28 (41.2)   21 (38.9)
                                ≥10                        40 (58.8)   33 (61.1)
  Sensitivity to chemotherapy                                          0.045
                                Sensitive                  50 (74.6)   31 (57.4)
                                Insensitive                17 (25.4)   23 (42.6)
  Recurrence status                                                    0.038
                                Relapse                    25 (36.8)   30 (55.6)
                                No relapse                 43 (63.2)   24 (44.4)

BMI, body mass index; OCCC, ovarian clear cell carcinoma; PD-L1, programmed death-ligand 1.

4. Survival analysis according to PD-L1 expression in OCCCs {#sec4___1}
-----------------------------------------------------------

The PFS and OS curves after surgery for patients who underwent complete resection are shown in [Fig. 3](#F3){ref-type="fig"}. On the whole, the 3- and 5-year OS were 74.9% and 60.7%, respectively ([Fig. 3A](#F3){ref-type="fig"}) and patients had an estimated median PFS of 62.9 months (95% confidence interval \[CI\]=24.1--101.7 months; [Fig. 3B](#F3){ref-type="fig"}). Patients with PD-L1^high^ was correlated with better survival outcome than those with PD-L1^low^ (5-year OS rate, 71.9% vs. 48.2%; p=0.001; [Fig. 3C](#F3){ref-type="fig"}). Similarly, PD-L1^high^ was associated with significantly shorter median PFS compared with PD-L1^low^ (52.0 months vs. not achieved in the study period; p=0.021; [Fig. 3D](#F3){ref-type="fig"}).

![(A, B) PFS and OS curves in patients with OCCC. (C) Patients with PD-L1^low^ (yellow solid line) presented a better survival outcome than those with PD-L1^high^ (blue dotted line). (D) Patients with PD-L1^high^ (blue dotted line) showed significantly worse PFS compared with those with low expression (yellow solid line).\
OCCC, ovarian clear cell carcinoma; OS, overall survival; PD-L1, programmed death-ligand 1; PD-L1^high^, high PD-L1 expression; PD-L1^low^, low PD-L1 expression; PFS, progression-free survival.](jgo-28-e77-g003){#F3}

In subgroup analysis, both PFS (p=0.978; [Fig. 4B](#F4){ref-type="fig"}) and OS (p=0.967; [Fig. 4A](#F4){ref-type="fig"}) curves were not significantly different between high and PD-L1^low^ in early stage (I--II) patients. However, patients with PD-L1^high^ experienced a poorer PFS (hazard ratio \[HR\]=1.926; p=0.044; [Fig. 4D](#F4){ref-type="fig"}) and OS (HR=2.492; p=0.021; [Fig. 4C](#F4){ref-type="fig"}) compared with those with PD-L1^low^ in advanced stages (III--IV). Meanwhile, both PFS (p=0.219; [Fig. 5B](#F5){ref-type="fig"}) and OS (p=0.662; [Fig. 5A](#F5){ref-type="fig"}) curves were not significantly different between PD-L1^high^ and PD-L1^low^ groups in PS patients. PD-L1^high^ exhibited a poorer OS compared with those with PD-L1^low^ in PR cases (median OS, 17.6 vs. 26.6 months; p=0.037; [Fig. 5C](#F5){ref-type="fig"}), whereas no favoring advantage in PFS was found (p=0.233; [Fig. 5D](#F5){ref-type="fig"}).

![PFS and OS curves stratified by FIGO stage between high and low PD-L1 expression (yellow solid lines, PD-L1^low^; blue dotted lines, PD-L1^high^, respectively). (A) OS curves between high and PD-L1^low^ in FIGO stage I/II cases. (B) PFS curves between high and PD-L1^low^ in FIGO stage I/II cases. (C) OS curves between high and PD-L1^low^ in stage III/IV cases. (D) PFS curves between high and PD-L1^low^ in stage III/IV cases. Patients with PD-L1^high^ revealed a worse OS and PFS compared with those with PD-L1^low^ in stage III/IV cases, with significant differences observed.\
FIGO, International Federation of Gynecology and Obstetrics; OCCC, ovarian clear cell carcinoma; OS, overall survival; PD-L1, programmed death-ligand 1; PD-L1^high^, high PD-L1 expression; PD-L1^low^, low PD-L1 expression; PFS, progression-free survival.](jgo-28-e77-g004){#F4}

![PFS and OS curves stratified by the sensitivity to chemotherapy between high and low PD-L1 expression (yellow solid lines, PD-L1^low^; blue dotted lines, PD-L1^high^, respectively). (A) OS curves between high and PD-L1^low^ in PS cases. (B) PFS curves between high and PD-L1^low^ in PS cases. (C) OS curves between high and PD-L1^low^ in PR cases. (D) PFS curves between high and PD-L1^low^ in PR cases. Patients with PD-L1^high^ revealed a worse OS and PFS compared with those with PD-L1^low^ in PR cases, with significant differences observed.\
OS, overall survival; PD-L1, programmed death-ligand 1; PD-L1^high^, high PD-L1 expression; PD-L1^low^, low PD-L1 expression; PFS, progression-free survival; PR, platinum-resistant; PS, platinum-sensitive.](jgo-28-e77-g005){#F5}

5. Univariate and multivariate analysis of possible risk factors affecting recurrence and OS in OCCCs {#sec5___1}
-----------------------------------------------------------------------------------------------------

In univariate analysis, tumor recurrence was significantly associated with PD-L1^high^ (HR=1.9; p=0.021), advanced stages (III--IV, HR=7.8; p\<0.001), high level of serum CA125 (HR=2.5; p=0.002), gross residual diseases (HR=2.9; p\<0.001), PR diseases (HR=31.3; p\<0.001), and bilateral tumor (HR=1.6; p=0.001). In addition, PD-L1^high^ (HR=2.9; p=0.001), advanced stages (III--IV, HR=11.8; p\<0.001), gross residual diseases (HR=4.5; p\<0.001), PR diseases (HR=21.0; p\<0.001), bilateral tumor (HR=1.9; p\<0.001), high level of serum CA125 (HR=2.2; p=0.023), and large tumor volume (HR=1.9; p=0.038) were predictive of a worse survival outcome ([Table 1](#T1){ref-type="table"}).

In multivariate analysis, PD-L1^high^ and advanced stages (III--IV) were adverse independent prognosticators for both PFS (HR~PD-L1~=2.0; p~PD-L1~=0.038; HR~stage~=10.2; p~stage~\<0.001, respectively; [Table 3](#T3){ref-type="table"}) and OS (HR~PD-L1~=3.0; p~PD-L1~=0.011; HR~stage~=14.3; p~stage~\<0.001, respectively; [Table 3](#T3){ref-type="table"}).

###### Multivariate Cox regression analysis with PFS and OS as endpoint

![](jgo-28-e77-i003)

  Factors                                                     PFS      OS                                                 
  ----------------------------------------------------------- -------- --------------- --------- -------- --------------- ---------
  Pretreatment serum CA125 level (\<244 U/mL vs. ≥244 U/mL)   0.922    0.457--1.860    0.820     0.578    0.259--1.292    0.182
  Ascitic fluid (positive vs. negative)                       1.110    0.883--3.566    0.107     1.111    0.511--2.414    0.790
  FIGO stage (advanced vs. early)                             10.165   4.513--22.894   \<0.001   14.323   4.744--43.240   \<0.001
  PD-L1 expression (high vs. low)                             1.970    1.039--3.737    0.038     3.032    1.285--7.153    0.011
  Tumor volume (\<10 cm vs. ≥10 cm)                           0.928    0.069--1.248    0.621     0.752    0.513--1.102    0.144
  Residual disease (\>1 cm vs. R~0~, ≤1 cm)                   1.063    0.566--1.999    0.849     1.767    0.824--3.787    0.143

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R~0~, no visible residual disease.

DISCUSSION
==========

This study demonstrates that PD-L1^high^ was observed in OCCC patients and was significantly associated with advanced stages, positive ascitic fluid, PR disease, and relapse of disease. Furthermore, PD-L1^high^ exhibited poorer PFS and OS than PD-L1^low^ among OCCC patients. More importantly, the unfavorable prognostic effect of PD-L1^high^ was identified as an independent predictor for survival.

In the present study, a significant association between PD-L1^high^ and advanced FIGO stage was identified. FIGO stage was previously confirmed to be strongly correlated with prognosis in OCCC patients. The significant correlation between PD-L1^high^ and advanced disease stage suggested the intense association between PD-L1 expression and tumor malignancy. Of note, a significant correlation between PD-L1^high^ and ascitic fluid was observed, confirming the metastatic behavior of the carcinomatous component. A separate study by Abiko et al. \[[@B23]\] demonstrated in his study that PD-L1 expression in OC is associated with increased invasiveness and peritoneal dissemination. Maine et al. \[[@B24]\] demonstrated that PD-L1 expression on monocytes in the ascites and blood of patients with malignant OC is strikingly higher than those with benign/borderline disease. Together with our study, these results supported that PD-L1 expression possibly reflected the interruption of the antitumor immunity of the host and might further be associated with tumor development in ovarian malignancies.

Currently, PD-L1 is thought as a key mechanism of immunosuppressive effect and allows the tumor to evade immune destruction. Multiple different tumors expressing PD-L1, including NSCLC \[[@B25]\], RCC \[[@B26]\], osteosarcoma \[[@B27]\], and advanced MEL \[[@B28]\], presented a relatively poor prognostic outcomes. However, some other studies exhibited a controversial result of PD-L1 expression on the survival outcome. Kluger et al. \[[@B29]\] reported a better OS in patients with malignant MELs associated with high levels of PD-L1 expression. Also Beckers et al. \[[@B30]\] demonstrated that cytoplasmic tumoral expression of PD-L1 was associated with a lower risk of specific death in triple-negative breast cancer (HR=0.45; p=0.035). Hamanishi et al. \[[@B18]\] demonstrated the elevated proportion of high expression of PD-L1 in OCs and a significantly poorer prognosis in patients with higher expression than those with lower expression (p=0.016). Although they found that tumoral PD-L1 expression was an independent predictor of poor prognosis in OCs, this study investigated different histological subtypes of OCs. Our result also described an unfavorable prognostic impact of PD-L1^high^ in OCCC, a specified histological subtype of ovarian carcinomas. However, a recent study showed a positive prognostic impact of PD-L1 expression in a cohort of 215 HGSOCs, which is in line with a recent study on a positive prognostic effect of programmed cell death-1 (PD-1) positive tumor infiltrating lymphocytes (TILs) in HGSOC \[[@B19][@B20]\]. These results also confirmed that the effect of PD-1 on recurrence and survival should be separately investigated based on different histologic subtypes of tumor.

The fact that PD-L1 is expressed in OCCC and that this expression has unfavorable prognostic impact strongly suggest that the PD-L1 may be an applicable prognostic predictor and monitor for OCCC patients in clinical practice. Previous studies in an OC mouse model showed that response to PD-L1 blockade requires a preexisting adaptive immunity in tumors, and tumors without TILs failed to respond \[[@B31]\]. This might make the anti-PD-L1 Abs available to OCCC. Anti-PD-L1 Abs have demonstrated durable responses in a number of different advanced malignancies. A phase I trial (NCT00729664) of BMS-936559, an anti-PD-L1 agent, showed that for the evaluable population, overall responses (ORs) were observed in patients with MEL (9/52), RCC (2/17), NSCLC (5/49), and OC (1/17). In 16 patients with ≥1 year of follow-up, stable disease (SD, ≥24 weeks) was observed in 14 patients with MEL, 6 patients with NSCLC, 3 patients with OC, and 7 patients with RCC \[[@B32]\]. Nivolumab, an anti-PD-1 antibody, demonstrated an efficacy in a proportion of relapsed PR OC patients, with the median PFS time was 3.5 months (95% CI=1.7--3.9), and the median OS time was 20.0 months \[[@B33]\]. In addition, the underlying mechanisms might be that in EOCs without lymphocyte infiltrates, PD-1/PD-L1 blockade is unlikely to be sufficient, and combinations will be required to mount a tumor-rejection adaptive immune response \[[@B34]\].

To our knowledge, this is the first report investigating PD-L1 expression and its correlation with clinicopathologic and prognostic characteristics in OCCC, a histologic subset of EOCs. The limitation in this study was that PD-L1 expression in this study was detected only with IHC, and no any other method was used to verify the PD-L1 expression status. Additional researches on proteomic markers or PD-L1 transcriptional levels in cell lines are required to further understand the mechanism of PD-1/PD-L1 pathway in tumoral immune suppression. Well-designed prospective studies with more patients are necessary in the future to clarify the associations between the expression levels of PD-L1 and the prognostic impact thereof.

In conclusion, the prognostic value of PD-L1 expression in OCCC patients might have the potential to enable more effective clinical approaches, including prognostic surveillance of patients and possible use of anti-PD-L1 Ab immunotherapy.
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